🍪 The GLP Lounge uses cookies to improve your experience, analyze traffic, and personalize content. By continuing to use this site, you agree to our Cookie Policy.
Evidence-based GLP-1 & peptide discussion since 2023
ForumsClinical Trials & ResearchNNC0519-0396: Novo next-gen oral GLP-1 — anyone have experience? Page 2

NNC0519-0396: Novo next-gen oral GLP-1 — anyone have experience?

EndoResFellow Sat, Jan 3, 2026 at 11:36 AM 15 replies 968 viewsPage 2 of 3
jason_paloalto
Member
212
890
Nov 2024
Palo Alto, CA
Jan 3, 2026 at 12:58 PM#6

One concrete data point for the thread. For anyone reading later: the numbers in this thread are worth checking against a primary source before you act on them, including mine. Half the figures circulating in this community trace back to a secondary summary that dropped a qualifier.

Last edited: Jan 3, 2026 at 5:58 PM
8 11tane_welly, Dr.PathRoch, mona_PHX and 5 others
Reply Quote Save Share Report
HealthEcon_DC
Member
567
3,456
Apr 2024
Washington, DC
Jan 3, 2026 at 1:30 PM#7

A narrower follow-up, since the general answer is now clear:

How much of the oral variability is the SNAC absorption window and how much is dose, because the two get conflated constantly?

9 12JessicaH_TX, KevinCompounds, TirzTom and 6 others
Reply Quote Save Share Report
paige_pharma
Member
289
1,234
Sep 2024
Omaha, NE
Jan 3, 2026 at 2:02 PM#8
jason_paloalto said:
For anyone reading later: the numbers in this thread are worth checking against a primary source before you act on them, including mine.

There is a second half to this that has not been said yet. Order of operations matters more than any single choice here: establish a baseline, change one thing, wait long enough for it to express itself, then measure again under the same conditions.

10 13adam_van, Dr.SurgeonPGH, rachel_ABQ and 7 others
Reply Quote Save Share Report

Sigma-Aldrich — Research-Grade Standards

Certified reference materials, analytical reagents, and research-grade standards for peptide verification. Trusted by laboratories worldwide.

Shop Reference Standards
EndoResFellow
Member
456
2,345
Sep 2024
Baltimore, MD
Jan 3, 2026 at 2:34 PM#9

OP back with an update, since a thread like this is useless without one.

I moved the tablet to the moment I wake up rather than trying to fit it around breakfast, and the difference in the following weeks was obvious. It was a timing problem, not a dose problem.

11 14NurseKim_ATL, paul_denver, TinaHashiRN and 8 others
Reply Quote Save Share Report
Dr.RaviCardio
VIP Member
2,890
15,678
Jan 2024
New York, NY
Jan 3, 2026 at 5:07 PM#10
paige_pharma said:
Order of operations matters more than any single choice here: establish a baseline, change one thing, wait long enough for it to express itself, then…

No disagreement with paige_pharma. One condition attached. The absorption variability is real, but it partly averages out over weeks — the steady-state trough is less erratic than any single day would suggest. Where it bites is in the first fortnight, when people conclude the tablet does nothing.

31 4jason_sac26, chris_chi24, tampaLisa73 and 28 others
Reply Quote Save Share Report

Similar Threads

FLOW trial: semaglutide renal outcomes — NEJM publication review14 replies
SELECT trial: semaglutide 2.4mg cardiovascular outcomes — 4yr data9 replies
TRIUMPH program (retatrutide) — Phase 3 trial design and endpoints13 replies
Orforglipron ATTAIN trials — oral non-peptide GLP-1 agonist8 replies
CagriSema (amylin + semaglutide) — REDEFINE Phase 3 results20 replies
ForumsNewTrendingMembersAccount

Log In

Forgot password?
No account? Register